Anti Inflammatory News and Research

RSS

$Higher levels of Omega-3 fatty acids may reduce risk for hip fractures in postmenopausal women$

Higher levels of Omega-3 fatty acids may reduce risk for hip fractures in postmenopausal women

Higher levels of omega-3 fatty acids in the blood may reduce the risk for hip fractures in postmenopausal women, recent research suggests.

28 Jun 2013

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of LEMTRADA (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features.

28 Jun 2013

Janssen receives complete response letter from FDA for XARELTO sNDA

Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome.

28 Jun 2013

Supreme Court sides with generic drug makers

The Supreme Court ruled on Monday that generic drugmakers cannot be sued under state law for adverse reactions to their products, a decision that consumer advocates called a blow to patient safety. In a 5-4 vote, the court ruled for Mutual Pharmaceutical Co, owned by Sun Pharmaceutical Industries Ltd, overturning a multimillion-dollar jury award to a badly injured patient in New Hampshire who alleged a generic drug she had taken was unsafe based on its chemical design (Hurley and Berkrot, 6/24).

26 Jun 2013

Primary care physicians prefer to prescribe NSAIDS for chronic pain, report shows

For treating the estimated 100 million Americans with chronic pain -- a population larger than those with heart disease, cancer and diabetes combined -- researched reported in The Journal of Pain shows that primary care physicians overwhelmingly prefer to prescribe non-steroidal anti-inflammatory medications, in accordance with published clinical practice guidelines.

26 Jun 2013

Study finds U-shaped association between consumption of fish and risk of developing AF

Moderation seems to be key when it comes to eating fish to prevent atrial fibrillation according to an observational study presented at the EHRA EUROPACE congress held 23 to 26 June in Athens, Greece.

25 Jun 2013

Doctoral research shows role of immune system in development of resistance to antibiotics

Leon Cantas' doctoral research shows that the immune response of the host to a bacterial infection may have a significant effect on the development of bacteria's resistance to antibiotics.

19 Jun 2013

Aspirin slows accumulation of DNA mutations in abnormal cells, points UCSF scientist

Aspirin is known to lower risk for some cancers, and a new study led by a UC San Francisco scientist points to a possible explanation, with the discovery that aspirin slows the accumulation of DNA mutations in abnormal cells in at least one pre-cancerous condition.

19 Jun 2013

Obesity in adolescents is associated with sensorineural hearing loss

Obese adolescents are more likely than their normal-weight counterparts to have hearing loss, according to results of a new study. Findings showed that obese adolescents had increased hearing loss across all frequencies and were almost twice as likely to have unilateral (one-sided) low-frequency hearing loss.

18 Jun 2013

Athera receives support from FP7 for development of fully human antibody PC-mAb

Athera Biotechnologies AB today announced that future development costs of its fully human antibody PC-mAb up until proof-of-concept will be co-funded by the European Union's Seventh Framework Programme for Research (FP7) through a collaborative research grant. Karolinska Development AB owns 65% of Athera Biotechnologies AB.

17 Jun 2013

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced results from PALACE 3, the Company's third phase III study in psoriatic arthritis (PsA), at EULAR, the European Congress of Rheumatology annual meeting in Madrid, Spain.

15 Jun 2013

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Celgene International Sàrl, a subsidiary of Celgene Corporation today presented results from a randomized, placebo-controlled phase II trial in patients with Behçet's disease at EULAR, the European Congress of Rheumatology annual meeting in Madrid.

14 Jun 2013

Ischaemic heart disease patients at risk after 1 week of treatment

New study data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate a high prevalence of NSAID prescriptions in patients at risk of ischaemic heart disease.

14 Jun 2013

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks.

13 Jun 2013

Study shows 1 in 8 patients at risk of developing serious ADE take OTC NSAIDs

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that one in eight patients at risk of developing a serious adverse drug event is taking over-the-counter non-steroidal anti-inflammatory drugs, often to treat a musculoskeletal complaint.

13 Jun 2013

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced 52-week results from PALACE 1, the Company's first phase III study in psoriatic arthritis at the European Congress of Rheumatology annual meeting in Madrid, Spain.

12 Jun 2013

Researchers to launch Phase II clinical trial to investigate potential new therapy for sickle cell anemia

Seeking to improve the lives of sickle cell anemia sufferers around the world, researchers from the La Jolla Institute for Allergy and Immunology, the Dana-Farber/Children's Hospital Cancer Center in Boston and the BloodCenter of Wisconsin in Milwaukee and others are preparing to launch Phase II of a clinical trial to investigate a potential new therapy for reducing the disorder's severest symptoms.

12 Jun 2013

Hebrew University student develops drug formulations to treat illnesses through skin applications

New, more efficient drug formulations designed to treat illnesses through skin applications -- thus avoiding serious side effects associated with oral drug-taking -- have been developed by a student at the Hebrew University of Jerusalem.

12 Jun 2013

New method allows omega-3 fatty acids to be added to popular foods

The omega-3 fatty acids contained in fatty salt-water fish are an important component of a healthy diet in humans. Despite being aware of this fact, Germans still do not eat enough fish. Now Fraunhofer researchers have developed a method that allows omega-3 fatty acids to be added to popular foods.

7 Jun 2013

Scientists discover protective role of retinoic acid against intestinal inflammation

Scientists at Trinity College Dublin have made novel discoveries around the protective influence of Vitamin A against the damaging immune responses that lead to inflammatory bowel disease.

5 Jun 2013

Anti Inflammatory News and Research

Higher levels of Omega-3 fatty acids may reduce risk for hip fractures in postmenopausal women

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Janssen receives complete response letter from FDA for XARELTO sNDA

Supreme Court sides with generic drug makers

Primary care physicians prefer to prescribe NSAIDS for chronic pain, report shows

Study finds U-shaped association between consumption of fish and risk of developing AF

Doctoral research shows role of immune system in development of resistance to antibiotics

Aspirin slows accumulation of DNA mutations in abnormal cells, points UCSF scientist

Obesity in adolescents is associated with sensorineural hearing loss

Athera receives support from FP7 for development of fully human antibody PC-mAb

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Ischaemic heart disease patients at risk after 1 week of treatment

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

Study shows 1 in 8 patients at risk of developing serious ADE take OTC NSAIDs

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Researchers to launch Phase II clinical trial to investigate potential new therapy for sickle cell anemia

Hebrew University student develops drug formulations to treat illnesses through skin applications

New method allows omega-3 fatty acids to be added to popular foods

Scientists discover protective role of retinoic acid against intestinal inflammation

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News